Document is current
Any future updates will be listed below
-
Authors
Valk, Anika M.
Koers, Jana
Derksen, Ninotska I. L.
Hogenboom, Laura
van Kempen, Zoé
Killestein, Joep
Rutgers, Abraham
Heeringa, Peter
Horváth, Barbara
Kuijpers, Taco W.
van Ham, S. Marieke
Brinke, Anja ten
van der Woude, Diane
Toes, René E. M.
Bos, Nicolaas A.
Rispens, Theo
,
Eftimov, Filip
Franssen, Casper F. M.
Groothoff, Jaap W.
Jacobs, Bart
Kater, Arnon
de Leeuw, Karina
Oosten, Liesbeth E. M.
van Paassen, Pieter
Scherer, Uli H.
Titulaer, Maarten J.
Verschuuren, Jan
de Vries, Niek
Vos, Josephine M. I.
Veelken, J. Hendrik
van Baarsen, Lisa
Eldering, Eric
van Els, Cecile A. C. M.
Hendriks, Rudi W.
Huijbers, Maartje G.
Huizinga, Ruth
Mebius, Reina E.
de Wit, Jelle
Damoiseaux, Jan G. M. C.
Abdulahad, Wayel
Ruiter, Annabel M.
van der Weele, Linda
Kielbassa, Karoline
Coppola, Mariateresa
Verhoeven, Dorit
Desai, Jyaysi
van der Burg, Mirjam
Vletter, Esther M.
Braham, Maaike
Busch, Matthias
Bonasia, Carlo
Raveling-Eelsing, Elisabeth
Verstegen, Niels
Marsman, Casper
Sciarillo, Rocco
Pollastro, Sabrina
Elias, George
van Dam, Koos
Paardekooper, Laurent M.
Ysermans, Renée
Corneth, Odilia B. J.
Buisman, Anne-Marie
van Binnendijk, Rob
van Schouwenburg, Pauline A.
Koning, Marvyn
Wieske, Luuk
Kummer, Laura Y.
Bos, Amelie
-
Funding
Funding for this research was provided by:
Universiteit van Amsterdam
Samenwerkende Gezondheidsfondsen (LSHM18055-SGF, LSHM18055-SGF, LSHM18055-SGF, LSHM18055-SGF, LSHM18055-SGF, LSHM18055-SGF, LSHM18055-SGF, LSHM18055-SGF, LSHM18055-SGF, LSHM18055-SGF, LSHM18055-SGF, LSHM18055-SGF)
Vasculitis Foundation
Landsteiner Foundation for Blood Transfusion Research (Grant1626)
- License Information
-
More Information
Article History
Received: 27 February 2025
Accepted: 17 April 2025
First Online: 28 April 2025
Declarations
:
: JK received research grants for multicentre investigator-initiated trials DOT-MS (NCT04260711, ZonMW), Supernext (NCT04225312, Treatmeds) and BLOOMS (NCT05296161, ZonMW and Treatmeds); received consulting fees from F Hoffmann-La Roche, Biogen, Teva, Merck, Novartis, and Sanofi/Genzyme (all payments to institution); reports speaker relationships with F Hoffmann-La Roche, Biogen, Immunic, Teva, Merck, Novartis, and Sanofi/Genzyme (all payments to institution); and is on the adjudication committee of MS clinical trials of Immunic (payments to institution only). All other authors declare no competing interests.
